Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting

Zug, Switzerland, Feb. 1, 2021 – Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the release of a late-breaker abstract that will be presented at the 2021 American Academy of Allergy Asthma & Immunology (AAAAI) Virtual Annual Meeting, to be held Feb. 26 through March 1, 2021.

The presentation details are as follows:

**Title:** PHA-022121: A Novel and Potent Bradykinin 2 Receptor Antagonist for Oral Treatment of Hereditary Angioedema

**Poster Number:** L23

**Poster Presenter:** Raf Crabbé, M.D.

The abstract will be published in the February 2021 online supplement of *The Journal of Allergy and Clinical Immunology.*

**About Pharvaris**

Pharvaris is a clinical-stage biopharmaceutical company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit [https://pharvaris.com/](https://pharvaris.com/).

**Investor Contact**

Chad Rubin, Solebury Trout  
[crubin@soleburytrout.com](mailto:crubin@soleburytrout.com)

**Media Contact**

Maggie Beller, Russo Partners, LLC  
[maggie.beller@russopartnersllc.com](mailto:maggie.beller@russopartnersllc.com)  
+1-646-942-5631